Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphoma classification update: B-cell non-Hodgkin lymphomas.

Manli Jiang1, N Nora Bennani2, Andrew L Feldman1

  • 1a Department of Laboratory Medicine and Pathology , Mayo Clinic , Rochester , MN , USA.

Expert Review of Hematology
|April 12, 2017
PubMed
Summary

The World Health Organization (WHO) classification of lymphomas, particularly B-cell non-Hodgkin lymphomas, has been updated. This revision impacts the subclassification and genetic stratification of diffuse large B-cell lymphoma and high-grade B-cell lymphomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026
Same author

Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study.

The American journal of surgical pathology·2026
Same author

Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.

British journal of haematology·2026
Same author

Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay.

Human pathology·2026
Same author

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.

American journal of hematology·2026

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Lymphoma classification is complex due to varying lymphocyte functions.
  • Genomic data add further complexity to lymphoma categorization.
  • The World Health Organization (WHO) system guides lymphoma classification based on consensus.

Purpose of the Study:

  • To review recent changes in lymphoma classification, focusing on B-cell non-Hodgkin lymphomas.
  • To summarize updates relevant to clinicians caring for lymphoma patients.
  • To highlight the impact of the 2016 WHO classification revision.

Main Methods:

  • Review of the 2016 revision to the WHO classification of lymphoid neoplasms.
  • Focus on B-cell non-Hodgkin lymphomas, the most common lymphoma group.
Keywords:
B-cell lymphomaNon-Hodgkin lymphomaWorld Health Organization (WHO)diffuse large B-cell lymphomafollicular lymphomalymphoma classificationmantle cell lymphoma

Related Experiment Videos

  • Synthesis of pathological, genetic, and clinical factors influencing classification.

    • Main Results:

    • The 2016 WHO classification revision significantly impacts diffuse large B-cell lymphoma and high-grade B-cell lymphomas.
    • Updates refine subclassification and genetic stratification for these aggressive lymphomas.
    • Evolving criteria and nomenclature are reflected for indolent B-cell lymphomas and lymphoproliferative disorders.

    Conclusions:

    • Lymphoma classification is dynamic, requiring integration of new clinical, pathological, and molecular insights.
    • The 2016 WHO revision enhances precision in diagnosing and stratifying B-cell lymphomas.
    • Accurate classification is crucial for effective patient management and treatment strategies.